Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase

Journal of Clinical Investigation

Volumn 117, Issue 4, 2007, Pages 1049-1057

  Iwamoto, Shotaro ^a   Mihara, Keichiro ^a   Downing, James R ^a,b   Pui, Ching Hon ^a,b   Campana, Dario ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL GROWTH; CHILD; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; ASPARTATE-AMMONIA LIGASE; BONE MARROW CELLS; CELL DIVISION; CHILD; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MESENCHYMAL STEM CELLS; POLYMERASE CHAIN REACTION;

EID: 34147153377     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30235     Document Type: Article

References (50)

1. Oettgen, H.F., et al. 1967. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 27:2619-2631.
2. Tallal, L., et al. 1970. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 25:306-320.
3. Pratt, C.B., Simone, J.V., Zee, P., Aur, R.J., and Johnson, W.W. 1970. Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia. J. Pediatr. 77:474-483.
4. Jaffe, N., et al. 1971. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 31:942-949.
5. Sutow, W.W., et al. 1971. L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group. Cancer. 28:819-824.
6. Ortega, J.A., et al. 1977. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 37:535-540.
7. Sallan, S.E., et al. 1983. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 43:5601-5607.
8. Reaman, G.H., Ladisch, S., Echelberger, C., and Poplack, D.G. 1980. Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia. Cancer. 45:3090-3094.
9. Pui, C.H., and Evans, W.E. 2006. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354:166-178.
10. Schrappe, M., et al. 2000. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 95:3310-3322.
11. Silverman, L.B., et al. 2001. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 97:1211-1218.
12. Duval, M., et al. 2002. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 99:2734-2739.
13. Pession, A., et al. 2005. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23:7161-7167.
14. Whitecar, J.P., Jr., Bodey, G.P., Harris, J.E., and Freireich, E.J. 1970. L-asparaginase. N. Engl. J. Med. 282:732-734.
15. Iiboshi, Y., Papst, P.J., Hunger, S.P., and Terada, N. 1999. L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem. Biophys. Res. Commun. 260:534-539.
16. Richards, N.G., and Kilberg, M.S. 2006. Asparagine synthetase chemotherapy. Annu. Rev. Biochem. 75:629-654.
17. Prager, M.D., and Bachynsky, N. 1968. Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. Biochem. Biophys. Res. Commun. 31:43-47.
18. Haskell, C.M., and Canellos, G.P. 1969. l-asparaginase resistance in human leukemia - asparagine synthetase. Biochem. Pharmacol. 18:2578-2580.
19. Hutson, R.G., et al. 1997. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am. J. Physiol. 272:C1691-C1699.
20. Aslanian, A.M., Fletcher, B.S., and Kilberg, M.S. 2001. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem. J. 357:321-328.
21. Stams, W.A., et al. 2005. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood. 105:4223-4225.
22. Stams, W.A., et al. 2003. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood. 101:2743-2747.
23. Appel, I.M., et al. 2006. Upregulation of asparagine synthetase expression is not linked to the clinical response to L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 107:4244-4249.
24. den Boer, M.L., Evans, W.E., and Pieters, R. 2005. TELAML1-positive ALL: a discordant genotype. Cell Cycle. 4:997-998.
25. Umiel, T., et al. 1986. Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation. Leuk. Res. 10:1007-1013.
26. Gluck, U., et al. 1989. Long-term proliferation of human leukemia cells induced by mouse stroma. Exp. Hematol. 17:398-404.
27. Manabe, A., Coustan-Smith, E., Behm, F.G., Raimondi, S.C., and Campana, D. 1992. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood. 79:2370-2377.
28. Makrynikola, V., and Bradstock, K.F. 1993. Adhesion of precursor-B acute lymphoblastic leukaemia cells to bone marrow stromal proteins. Leukemia. 7:86-92.
29. Nishigaki, H., et al. 1997. Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia. Blood. 89:3735-3744.
30. Kumagai, M., et al. 1996. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J. Clin. Invest. 97:755-760.
31. Mihara, K., et al. 2003. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br. J. Haematol. 120:846-849.
32. Fine, B.M., Kaspers, G.J., Ho, M., Loonen, A.H., and Boxer, L.M. 2005. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res. 65:291-299.
33. Ding, Y., Li, Z., and Broome, J.D. 2005. Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines. Leukemia. 19:420-426.
34. Wang, H., et al. 2000. Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placenta. Biochem. Biophys. Res. Commun. 273:1175-1179.
35. Hatanaka, T., et al. 2000. Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A. Biochim. Biophys. Acta. 1467:1-6.
36. Holleman, A., et al. 2004. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351:533-542.
37. Raff, M.C. 1992. Social controls on cell survival and cell death. Nature. 356:397-400.
38. Manabe, A., et al. 1994. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood. 83:758-766.
39. Bradstock, K., Bianchi, A., Makrynikola, V., Filshie, R., and Gottlieb, D. 1996. Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma. Leukemia. 10:813-820.
40. LeBien, T.W. 2000. Fates of human B-cell precursors. Blood. 96:9-23.
41. Scadden, D.T. 2006. The stem-cell niche as an entity of action. Nature. 441:1075-1079.
42. Moore, K.A., and Lemischka, I.R. 2006. Stem cells and their niches. Science. 311:1880-1885.
43. Matsunaga, T., et al. 2003. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9:1158-1165.
44. Mudry, R.E., Fortney, J.E., York, T., Hall, B.M., and Gibson, L.F. 2000. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 96:1926-1932.
45. Konopleva, M., et al. 2002. Stromal cells prevent apoptosis of AML cells by up-regulation of antiapoptotic proteins. Leukemia. 16:1713-1724.
46. Ito, C., et al. 1996. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 14:2370-2376.
47. Campana, D., Manabe, A., and Evans, W.E. 1993. Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia. 7:482-488.
48. Li, J., Law, H.K., Lau, Y.L., and Chan, G.C. 2004. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br. J. Haematol. 127:326-334.
49. Takagaki, K., et al. 2003. cDNA microarray analysis of altered gene expression in Ara-C-treated leukemia cells. Biochem. Biophys. Res. Commun. 309:351-358.
50. Ross, M.E., et al. 2003. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 102:2951-2959.